Genprex, Inc. (GNPX): Price and Financial Metrics


Genprex, Inc. (GNPX): $1.50

0.01 (+0.67%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GNPX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GNPX Stock Price Chart Interactive Chart >

Price chart for GNPX

GNPX Price/Volume Stats

Current price $1.50 52-week high $4.07
Prev. close $1.49 52-week low $1.17
Day low $1.47 Volume 115,600
Day high $1.53 Avg. volume 3,923,483
50-day MA $1.83 Dividend yield N/A
200-day MA $2.12 Market Cap 71.85M

Genprex, Inc. (GNPX) Company Bio


Genprex, Inc., a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome. The company was founded in 2009 and is based in Austin, Texas.


GNPX Latest News Stream


Event/Time News Detail
Loading, please wait...

GNPX Latest Social Stream


Loading social stream, please wait...

View Full GNPX Social Stream

Latest GNPX News From Around the Web

Below are the latest news stories about Genprex Inc that investors may wish to consider to help them evaluate GNPX as an investment opportunity.

How to Profit From Solar Energy

Once regarded as too expensive and inefficient, solar energy is now becoming a more viable option for both consumers and businesses.

Yahoo | February 20, 2022

Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022

Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional InvestorsNEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its quarterly Emerging Growth Invitational investor conference on February 24, 2022. The conference, which is open to all retail and institutional investors, will consist of a series of twenty five

Yahoo | February 15, 2022

Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes

AUSTIN, Texas, February 09, 2022--Genprex announces participation in February conferences.

Yahoo | February 9, 2022

This Biotech Company Has Cancer and Diabetes Treatments in Development

Real Money''s Timothy Collins says Genprex has persevered in the face of successive setbacks.

The Street | January 31, 2022

Preclinical study suggests potential use of Genprex ONCOPREX in colon cancer

Genprex <> said its collaborators published positive preclinical data for the use of its ONCOPREX Nanoparticle Delivery System to deliver a FAS DNA plasmid to treat

Seeking Alpha | January 27, 2022

Read More 'GNPX' Stories Here

GNPX Price Returns

1-mo -5.06%
3-mo -32.74%
6-mo 0.00%
1-year -59.89%
3-year -7.41%
5-year N/A
YTD 14.50%
2021 -68.43%
2020 1,196.88%
2019 -70.91%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6188 seconds.